Introduction
Saccharomyces boulardii , a non-pathogenic yeast when used as a probiotic, has been shown to be effective in the prevention and/or treatment of intestinal disorders, including antimicrobial-associated diarrhea, recurrent Clostridium diffi cile disease, acute diarrhea in adults and children induced by a variety of enteric pathogens, traveler ' s diarrhea and relapses of Crohn ' s disease or ulcerative colitis [1 -4] .
Several studies have shown that oral administration of S. boulardii is a safe and well-tolerated treatment [1, 5] . However, there are also several documented reports of S. boulardii fungemia and septicemia associated with oral administration of this organism when used as a probiotic in immunocompetent and immunocompromised patients [6 -10] .
Experiments in animals have shown that S. boulardii remains in the gut only during the period of its oral containing one of the 3 different dosage schedules of the probiotic for 14 days, as shown in Table 1 . The remaining 10 mice of each group served as controls and received normal saline at the same schedule, volume (300 μ l), and route.
Baseline stool cultures for yeasts were performed for all animals of the groups A, B, and C. Quantitative stool cultures were performed on the last day of treatment, and 1 and 2 weeks after the end of treatment.
On the last day of treatment, 10 mice from each group were randomly selected (by a technician not participating in the study), sacrifi ced by cervical dislocation and dissected. The lungs, heart, kidneys, liver and spleen were separately weighed and homogenized in 10 ml of saline solution. One hundred microlitres from the resulting suspension of each organ were inoculated onto plates containing Columbia agar with 5% sheep blood (BioMerieux, Marcy-l ' Etoile, France) and Sabouraud dextrose agar with chloramphenicol (Diagnostics Pasteur, Marnes le Coquette, France) and incubated at 37 ° C for 48 h.
Histopathological examination was performed on all organs by the same pathologist. The biopsy specimens were fi xed rapidly in 10% formalin and were subsequently embedded in paraffi n and stained with periodic acid-Schiff (PAS) and Gomori ' s methenamine silver (GMS) to detect tissue invasion by the yeasts.
The 40 mice in the fourth group were given per os a 300 μ l suspension containing 1.28 mg of the probiotic every 12 h for 2 weeks. Subsequently, starting on the day of discontinuation of the administration of the probiotic, the mice were fed special chow containing C. albicans at a median concentration of 1.5 ϫ 10 7 CFU/g for a period of 2 weeks, as previously described [15] . Special attention was paid by animal caretakers that mice were consuming the appropriate quantity of food which was provided on a daily basis after consumption of the food from the previous day.
Baseline stool cultures for yeasts were performed for all animals of the fourth group. Quantitative stool cultures were performed on the last day of the probiotic administration, and 1, 2, 3, and 4 weeks after its discontinuation.
The 40 mice in the fi fth group were given per os a 300 μ l suspension of 1.28 mg of the probiotic every 12 h for 4 weeks. On day 15 of treatment the mice were given chow containing C. albicans at a median concentration of 1.5 ϫ 10 7 CFU/g for a period of 2 weeks [15] .
Baseline stool cultures for yeasts were performed for all animals of the fi fth group. Quantitative stool cultures were performed 2, 3, 4, 5 and 6 weeks after the initiation of the probiotic treatment.
Stool cultures
An average of fi ve pieces of stool, weigh approximately 0.1 gram, were collected each time from each animal. Four grams of feces were collected from each group of 40 mice and cultured by mixing each gram of stool with 9 ml of sterile isotonic saline (0.9%) and emulsifying in a vortex mixer. Samples were then serially diluted in normal sterile saline. Susequently, 0.1 ml from each dilution was inoculated onto the selective, differential medium, Colorex Candida agar (E&O Laboratories Limited, Scotland) and incubated at 37 ° C for 48 h. Quantitation and identifi cation of different yeast colonies were performed at the end of this incubation period with the lowest detectable concentration of yeasts measuring 10 2 CFU/g of stool.
Approval for all experiments was granted from the relevant ethics committee.
Statistical analysis
Statistical analysis was performed with the use of graph Pad Prism software (version 5). We analyzed the median and range of yeast CFU/gr of stool for each group of mice. Statistically signifi cant differences in yeast CFUs across different groups of mice were analyzed by using the Mann-Whitney for two-sample comparisons and the Kruskal-Wallis test for several independent samples. P values of Ͻ 0.05 were considered statistically signifi cant for all comparisons.
Results
While yeasts were not recovered in baseline cultures, samples from the fi rst three groups (A, B, C), taken on day 14 Median S. boulardii concentrations (range) (log 10 CFU/g of stool)
Time period Group A Group B Group C Day 14 of administration 5.2 (4.9 -5.5) 6.8 (6.7 -6.9) 7.7 (7.0 -8. a probiotic. On day 14 of special diet, the concentration of C. albicans increased to 5.5 CFU/g of stools.
Stool cultures done 14 days after the end of the C. albicans supplemented diet showed that C. albicans persisted in a concentration of 4.2 log 10 CFU/g of stools (Table 4) .
Discussion
S. boulardii , the probiotic strain of S. cerevisiae , is considered to be non-pathogenic and is widely used for the prevention and/or treatment of several types of diarrhea [1 -3,17] . The benefi ts of the probiotic are thought to be related to direct enzymatic effects, modulation of the gut endogenous fl ora and enhancement of the immune response [18, 19] . Oral administration of S. boulardii in the form of capsules containing the yeast in a lyophilized form has traditionally been considered safe. However, several reports of S. cerevisiae fungemia associated with its probiotic use have been published [6 -10] . Lherm et al . [6] reported seven cases of systemic fungal infection in a series of 1395 intensive care unit (ICU) patients treated with S. boulardii . The authors concluded that the incidence of fungemia might be approximately fi ve per 1000.
Most patients with S. boulardii fungemia were immunosuppressed due to corticosteroids or immunosuppressive agents, hematopoietic stem cell transplantation, malignant haematological diseases, neutropenia, diabetes, human immunodefi ciency virus (HIV) infection and/or neonate state [7, 8] . However, there are reports of S. boulardii fungemia in critically ill patients with no obvious immunosuppression [9, 10] .
The source of the fungemia is thought to be the digestive tract, as has been documented in experimental studies for C. albicans [20] . Enteral translocation of ingested S. boulardii appears to be the main portal of entry into the bloodstream, especially in patients receiving high doses of the yeast along with antibiotics anaerobic activity [21] . This route was confi rmed by light and scanning electron microscopy of treatment with S. boulardii did yield the yeasts at concentrations which varied depending on the dose administered. The mice receiving the high dosage (group C) showed a statistically signifi cant increase in the GI concentration of S. boulardii of 7.7 log 10 CFU/g of stool when compared to the mice administered low doses (group A) and median concentrations (group B) dosages ( P ϭ 0.005 for group C vs. group A P ϭ 0.022 for group C vs. group B). The median dosage caused an increase of 6.8 log 10 CFU/g of stool and the low dosage caused a minor increase of 5.2 log 10 CFU/g of stools. Stool cultures taken 1 week after the end of treatment showed a signifi cant reduction of the yeast concentrations in all groups (Table 2) . No S. boulardii was recovered from stool specimens taken 2 weeks after discontinuation of treatment in all groups (Table 2) . No S. boulardii was detected in the stools of mice given saline, serving as controls. There was no histopathological or microbiological evidence of Saccharomyces dissemination and/or infection in any of the examined organs or in cultures initiated with portions of tissue from the same organs.
Regarding the fourth group, no yeasts were isolated in baseline cultures. Stool specimens taken on day 14 of treatment with S. boulardii showed that the level of GI colonization of mice caused an increase of 5.1 log 10 CFU/g of stools. Stool cultures taken 1 week after the end of treatment and the initiation of the special diet containing C. albicans showed a signifi cant increase in the concentration of C. albicans to the level of 7.8 log 10 CFU/g of stools and reduction of S. boulardii to 2.0 log 10 CFU/g of stools. No S. boulardii was isolated from the stool samples taken 2, 3, and 4 weeks after discontinuation of treatment. In contrast, the concentration of C. albicans gradually declined signifi cantly, reaching a concentration of 4.25 log 10 CFU/g of stools ( P Ͻ 0.0001; Table 3 ).
Regarding the fi fth group, again no yeast was found in baseline cultures. Stool cultures done 2 weeks after the probiotic initiation showed that faecal S. boulardii concentration was 5.1 log 10 CFU/g of stool, while 2 weeks later it had increased to 7.2 log 10 CFU/g of stools, but disappeared a week after the discontinuation of using it as examination of specimens prepared from the intestine of BALB/c mice given the yeast by intubation at a dosage of 1.5 g/kg every 6 h for up to 48 h [13] . In addition, translocation of S. boulardii to mesenteric lymph nodes, and rarely to the liver and spleen has been observed in immunosuppressed mice treated with excessively high yeast dose (10 mg) [14] .
We have described a model of GI colonization by C. albicans in healthy adult mice that mimics the same process in humans [11, 22, 23] . Based on this experience we used a similar model to study the effects on GI colonization of three different S. boulardii dose regimens given per os to mice. We observed that the higher the dose, the greater the intestinal concentration of S. boulardii but this GI colonization was not sustained. Dissemination of the yeast to internal organs did not occur, despite administration of high doses of the probiotic. This is most probably due to the fact that the mice in the present experiments were young and healthy and the doses were not excessively high as described by other authors [13, 14] . Most cases of dissemination have been observed in immunocompromised or critically ill individuals [6 -9] .
The present experiments were the fi rst to evaluate the role of S. boulardii in healthy young mice. Immunosuppressed animals were not used since the purpose of the study was to investigate the virulence and potential dissemination of the yeast when given as probiotic, in healthy hosts. Furthermore, the data from the study is to be used as the basis for comparison in future studies with immunocompromised animals.
Previous studies in animals have demonstrated that S. boulardii reaches a steady-state gut concentration quickly and maintains a high stable level as long as the yeast is taken daily. Once administration is discontinued, S. boulardii is quickly eliminated from the gut [11, 12] . It has also been confi rmed that the yeast is located in the intestinal lumen and is not associated with the mucosa [12] . Orally administered S. boulardii does not permanently colonize the intestinal tract of mice and does not alter the faecal fl ora [12] .
Similar fi ndings were reported when S. boulardii was used in healthy volunteers [24, 25] . It is of note that no morphological alterations of the human intestinal mucosa have been observed after treatment with high doses of lyophilized S. boulardii (250 mg four times per day) for 2 weeks [26] .
The present experiments have also shown that S. boulardii at the doses given does not prevent murine intestinal colonization by C. albicans in healthy young adult mice. These fi ndings confi rm previous reports describing that in monoxenic mice harbouring S. boulardii , C. albicans became established at a level equivalent to that observed in mice harbouring C. albicans alone [27] . Similarly other investigators demonstrated that S. boulardii did not decrease GI population levels of C. albicans , Clostridium diffi cile, Salmonella typhimurium or Shigella fl exneri in experimental mouse models [28 -30] . However, in contrast to these previous reports, S. boulardii has been shown to antagonize C. albicans in gnotobiotic mice and in mice with chemically-induced colitis [27, 31] , as well as E. coli in healthy volunteers [32] .
In conclusion, our data suggest that S. boulardii induces a substantial increase in the intestinal yeast concentration, when given by mouth in high doses. However, these increases are not sustained and not associated with dissemination of the yeast to internal organs in healthy young adult mice. Additionally, S. boulardii given in commonly used dosage does not prevent GI murine colonization by C. albicans .
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